Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
March 6th, 2023
Presentation of data from our pipelineat the American Association for Cancer Research Annual Meeting 2024
Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the researchand development of novel therapies for cancer, will present new data at the American
Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, in San
Diego, California.
Five presentations will be given on Chordia's pipeline of CLK inhibitor CTX-712,
CDK12 inhibitor CTX-439, and a GCN2 inhibitor.
Presentation on CTX-712, CLK inhibitor

Abstract No
Title

Session No
Time
Abstract No
Title
Session NoTime
Abstract No
Title
Session No
TimeCT115
A first-in-human phase I study of CTX-712 in patients withadvanced, relapsed or refractory malignant tumors (CTX-712-CL01 study): Efficacy and safety in a hematologic malignancies
cohortPoster Section 48
Monday Apr 8, 2024, 1:30 PM - 5:00 PMCT110
A first-in-human phase I study of CTX-712 in patients withadvanced, relapsed or refractory malignant tumors (CTX-712-CL01 study): Efficacy and safety in solid tumor cohorts
Poster Section 48
Monday Apr 8, 2024, 1:30 PM - 5:00 PM2081
Biomarkers for CLK inhibitor CTX-712 treatment response in
myeloid neoplasms: Paving the way toward clinical trials
Poster Section 29
Monday Apr 8, 2024, 9:00 AM - 12:30 PM

Presentation on CTX-439, CDK12 inhibitor

Abstract No
Title
Session NoTime3301
Translational Research of CDK12/13 Inhibitor, CTX-439,
Informing Clinical Trial Strategy
Poster Section 27
Monday Apr 8, 2024, 1:30 PM - 5:00 PM

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

Presentation on GCN2 inhibitor

Abstract No
Title
Session NoTime1233
Novel inhibitor targeting triple integrated stress response kinase
HRI, PERK, and GCN2 provides new insights into overcoming
resistance to proteasome inhibitors in multiple myelomaMinisymposium
Sunday Apr 7, 2024, 3:00 PM - 5:00 PM

About CTX-712
CTX-712 is a first-in-class, orally available, and selective small molecule inhibitor of
CDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays animportant role in cell growth. For more information, please visit: jRCT2080224127 fordetails on the Japan phase 1 clinical trial and clinicaltrials.gov/ (NCT05732103) for
details on the US Phase 1/2 clinical trial of CTX-712.
About Chordia Therapeutics
Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture,
Japan, is developing novel cancer therapies. Chordia’s lead asset, CLK inhibitor CTX712, is currently in Phase 1 clinical study in Japan and Phase1/2 clinical study in theUS. CTX-712 potentially targets vulnerabilities in cancer and could benefits patientswith various types of cancer. In addition to CTX-712, Chordia is researching several
preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective
in cancers with specific abnormalities, as well as GCN2 inhibitors.
Established:
Address:Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, please contact Mizobe in IR: ir@chordiatherapeutics.com